<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055909</url>
  </required_header>
  <id_info>
    <org_study_id>MOT-C-203</org_study_id>
    <secondary_id>2018-004827-36</secondary_id>
    <nct_id>NCT04055909</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock</brief_title>
  <acronym>ASTONISH</acronym>
  <official_title>Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotrem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inotrem</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled dose-selection study in which two
      doses of nangibotide are tested versus placebo.

      All patients with a diagnosis of septic shock will be considered for study participation. All
      potential study patients will receive standard of care for the treatment of septic shock.

      After screening for eligibility, patients meeting all inclusion and no exclusion criterion
      will be randomized. Patients will be randomized to one of three treatment arms.

      Treatment with study drug must be initiated as early as possible, but no later than 24 hours
      after the onset of septic shock, defined by the start of vasopressor therapy.

      Patients will be treated for at least 3 days with study drug. After the first 3 days of
      treatment, patients still requiring vasopressor will be treated until 24 hours after
      vasopressor withdrawal with a maximum treatment duration of 5 days.

      Patients will be assessed at the End of Study (EoS) visit at day 28. After the last patient's
      day 28 visit, the study will be analyzed. Additional follow up (FU) visits will be conducted
      after 90 days, 6 and 12 months.

      The objective of the study ist to compare the safety, tolerability and efficacy of two doses
      of nangibotide versus placebo, when given in addition to standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequential organ failure assessment (SOFA) score</measure>
    <time_frame>day 5</time_frame>
    <description>Change of total SOFA score from baseline to day 5 (in the subgroup defined by patients with elevated sTREM-1 baseline levels and in the overall population)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>day 28</time_frame>
    <description>Survival and all-cause mortality on D28</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>nangibotide 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>nangibotide 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nangibotide low dose</intervention_name>
    <description>nangibotide 0.3 mg/kg/h</description>
    <arm_group_label>nangibotide 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nangibotide high dose</intervention_name>
    <description>nangibotide 1.0 mg/kg/h</description>
    <arm_group_label>nangibotide 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent

          2. Age 18 to 85 years (inclusive)

          3. Documented or suspected infection: lung, abdominal or urinary tract infection (UTI) in
             the elderly (≥65 years)

          4. Organ dysfunction defined as acute change in total SOFA score ≥ 2 points

          5. Refractory hypotension requiring vasopressors to maintain MAP ≥65mm Hg despite
             adequate volume resuscitation

          6. Hyperlactatemia (blood lactate &gt;2 mmol/L or 18 mg/dL).

        Exclusion Criteria:

          1. Previous episode of septic shock requiring vasopressor administration within current
             hospital stay

          2. Underlying concurrent immunodepression with anti-CD52 alemtuzumab (Campath) or
             glucocorticoids &gt;75 mg prednisone daily or equivalent for more than 7 days

          3. Immunosuppressive therapy related to recent (&lt;6 months) transplantation

          4. Cancer chemotherapy (&lt;3 months) implying an immunodepression

          5. Known HIV infection with low CD4 cell count (&lt;200) for at least 6 months

          6. Known pregnancy (positive urine or serum pregnancy test)

          7. Shock of any other cause, e.g. hypotension related to gastrointestinal bleeding

          8. Ongoing documented or suspected endocarditis

          9. End-stage neurological disease

         10. End-stage cirrhosis (Child Pugh Class C)

         11. Acute Physiology and Chronic Health Evaluation (APACHE II) score &lt;15 or ≥ 34

         12. Home oxygen therapy on a regular basis for &gt; 6 h/day

         13. Recent cardiopulmonary resuscitation (CPR) (within current hospital stay)

         14. Body mass index (BMI) ≥ 40 kg/m2or weight ≥ 130 kg

         15. Moribund patients

         16. Decision to limit full care taken before obtaining informed consent

         17. Participation in another interventional study in the 3 months prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Jacques Garaud, MD</last_name>
    <role>Study Director</role>
    <affiliation>CEO and Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Jacques Garaud, MD</last_name>
    <phone>+33 (0)9 66 81 79 00</phone>
    <email>astonish@inotrem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Francois Laterre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Francois, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Ferrer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic Shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

